LivaNova (NASDAQ:LIVN – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13, Briefing.com reports. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The business had revenue of $362.30 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same period in the prior year, the firm earned $0.88 earnings per share. LivaNova’s revenue was up 14.3% compared to the same quarter last year. LivaNova updated its FY 2026 guidance to 4.200-4.300 EPS.
Here are the key takeaways from LivaNova’s conference call:
- Company raised full-year 2026 guidance to 7%–8% revenue growth and increased adjusted EPS to $4.20–$4.30, reflecting stronger-than-expected Q1 performance and continued top-line momentum.
- Cardiopulmonary strength: HLM revenue grew in the high teens driven by Essenz upgrade adoption, consumables gained share, and a new manufacturing line (2H26) plus supplier improvements should enable low double-digit output growth and upside to consumables supply.
- Epilepsy tailwinds: U.S. Medicare reimbursement for VNS increased ~48% for new implants (effective Jan 1, 2026) and favorable core VNS study data are improving pricing, reducing discounts, and expected to expand procedure penetration over time.
- Major regulatory and clinical milestones in OSA — FDA PMA approval of the aura6000 and 12‑month OSPREY RCT results (plus PolySync conversion data) materially de‑risk commercialization, but near‑term reimbursement ambiguity and market dynamics leave timing/scale of uptake uncertain.
- Near‑term cash and FCF pressure: cash declined to $540M, adjusted free cash flow was only $4M in Q1 due to higher capital spend and working capital, and full‑year capex is planned at $120M, weighing on short‑term cash conversion.
LivaNova Stock Up 15.1%
Shares of NASDAQ:LIVN traded up $8.67 during midday trading on Wednesday, reaching $66.26. 1,932,805 shares of the company were exchanged, compared to its average volume of 782,619. LivaNova has a fifty-two week low of $39.36 and a fifty-two week high of $71.92. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $63.97 and a two-hundred day simple moving average of $62.03. The firm has a market cap of $3.64 billion, a PE ratio of -14.86 and a beta of 0.82.
Analyst Ratings Changes
Check Out Our Latest Research Report on LIVN
Institutional Investors Weigh In On LivaNova
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC acquired a new stake in shares of LivaNova during the fourth quarter worth $302,000. First Trust Advisors LP acquired a new stake in shares of LivaNova during the second quarter worth $270,000. Vestcor Inc acquired a new stake in shares of LivaNova during the third quarter worth $251,000. Persistent Asset Partners Ltd acquired a new stake in shares of LivaNova during the fourth quarter worth $241,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of LivaNova during the third quarter worth $240,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
LivaNova News Summary
Here are the key news stories impacting LivaNova this week:
- Positive Sentiment: Q1 beat consensus on both EPS and revenue — EPS $0.98 vs. $0.85 expected; revenue ~$362.3M, up ~14% year‑over‑year — supporting the rally. LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
- Positive Sentiment: Company raised FY‑2026 guidance: adjusted EPS guide of 4.20–4.30 (aboveStreet consensus) and revenue guidance roughly $1.4B–$1.5B — this upward revision is the primary driver of positive sentiment. LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Positive Sentiment: Analyst/press coverage highlighted the outlook boost, which supported the stock’s gains as investors re‑price the company closer to the improved FY estimate. LivaNova Shares Rise After Outlook Boost
- Neutral Sentiment: Conference-call materials and slides were posted (useful for investors wanting management commentary on growth drivers, reimbursement tailwinds and margin outlook). Listen to Conference Call
- Neutral Sentiment: Trading activity spiked versus the average volume, indicating strong short‑term investor interest but also potential for intra‑day volatility as the market digests the guidance. MarketBeat LIVN Summary
- Negative Sentiment: Some coverage flagged a cautious investor reaction to aspects of the guidance (revenue midpoint vs. some expectations and forward visibility), which led other outlets to report modest share weakness in early trading despite the beat. LivaNova beats estimates but shares fall 2% on guidance concerns LivaNova (LIVN) beats quarterly expectations but shares slip on cautious guidance reaction
LivaNova Company Profile
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
See Also
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
